Tarsus Pharmaceuticals, Inc.

TARS

$73.83

Name : Tarsus Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,640,229,120.00

EPSttm : -15.86

Tarsus Pharmaceuticals, Inc.

$73.83

4.22%

$2.99

TARS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.29

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

0.22

EPS Last/This Y

-13.33

EPS This/Next Y

15.11

Price

73.94

Target Price

102.7

Analyst Recom

1.09

Performance Q

5.45

Upside

-819.6%

Beta

0.34

Ticker: TARS

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	TARS	74.43	1.01	0.09	14080
2026-10-13	TARS	70.79	1.00	0.93	14101
2026-10-14	TARS	72.36	1.00	0.89	14108
2026-10-15	TARS	70.99	1.00	0.13	14128
2026-10-16	TARS	68.1	1.00	1.11	14122
2026-10-19	TARS	69.44	0.77	0.33	1667
2026-10-20	TARS	70.97	0.77	1.04	1677
2026-10-21	TARS	70.46	0.81	0.00	2019
2026-10-22	TARS	72.08	0.80	0.11	2030
2026-10-23	TARS	68.12	0.79	0.00	2051
2026-10-26	TARS	70.05	0.79	0.13	2057
2026-10-27	TARS	70.79	0.78	0.21	2064
2026-10-28	TARS	72.13	0.78	0.18	2074
2026-10-29	TARS	74.21	0.78	0.30	2071
2026-10-30	TARS	76.37	0.76	0.25	2131
2026-11-02	TARS	73.38	0.74	0.60	2202
2026-11-03	TARS	72.61	0.74	1.80	2215
2026-11-04	TARS	69.04	0.75	0.15	2230
2026-11-05	TARS	67.42	0.64	2.00	2538
2026-11-06	TARS	68.57	0.64	0.38	2542
2026-11-09	TARS	70.88	0.64	3.80	2595
2026-11-10	TARS	73.81	0.65	0.00	2612
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	TARS	74.43	-100.0	-	-5.77
2026-10-13	TARS	70.87	-100.0	-	-5.77
2026-10-14	TARS	72.32	-100.0	-	-5.77
2026-10-15	TARS	70.97	-100.0	-	-5.77
2026-10-16	TARS	68.13	-100.0	-	-5.67
2026-10-19	TARS	69.44	-100.0	-	-5.67
2026-10-20	TARS	69.44	-100.0	-	-5.67
2026-10-21	TARS	70.97	-100.0	-	-4.88
2026-10-22	TARS	72.15	-100.0	-	-4.88
2026-10-23	TARS	68.13	-100.0	-	-4.88
2026-10-26	TARS	70.01	-100.0	-	-5.79
2026-10-27	TARS	70.77	-100.0	-	-5.79
2026-10-28	TARS	72.07	-100.0	-	-5.79
2026-10-29	TARS	74.16	-100.0	-	-5.79
2026-10-30	TARS	74.88	-100.0	-	-5.79
2026-11-02	TARS	73.33	-100.0	-	-5.79
2026-11-03	TARS	72.65	-100.0	-	-5.79
2026-11-04	TARS	69.07	-100.0	-	-5.79
2026-11-05	TARS	67.55	-100.0	-	-5.79
2026-11-06	TARS	68.52	-100.0	-	-5.79
2026-11-09	TARS	70.85	-100.0	-	-5.79
2026-11-10	TARS	73.94	170.0	-	-14.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	TARS	-3.67	3.56	13.76
2026-10-13	TARS	-3.67	3.56	13.76
2026-10-14	TARS	-3.67	3.56	13.76
2026-10-15	TARS	-3.67	3.56	13.76
2026-10-16	TARS	-3.49	3.56	13.76
2026-10-19	TARS	-3.67	2.98	13.71
2026-10-20	TARS	-3.91	2.98	13.71
2026-10-21	TARS	-3.72	2.98	13.01
2026-10-22	TARS	-3.72	2.98	13.01
2026-10-23	TARS	-3.72	2.98	13.01
2026-10-26	TARS	-3.72	2.77	13.01
2026-10-27	TARS	-3.72	2.77	12.29
2026-10-28	TARS	-3.72	2.77	12.29
2026-10-29	TARS	-3.72	2.77	12.29
2026-10-30	TARS	-3.72	2.77	12.29
2026-11-02	TARS	-3.72	2.78	12.29
2026-11-03	TARS	-3.72	2.78	12.29
2026-11-05	TARS	-3.72	2.78	12.29
2026-11-06	TARS	-3.72	2.78	12.29
2026-11-09	TARS	-3.72	1.34	12.29
2026-11-10	TARS	-3.72	1.34	12.29
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.78

Avg. EPS Est. Current Quarter

0.14

Avg. EPS Est. Next Quarter

-0.56

Insider Transactions

-3.72

Institutional Transactions

1.34

Beta

0.34

Average Sales Estimate Current Quarter

209

Average Sales Estimate Next Quarter

200

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

19.2

Max Drawdown 5-Year %

-60.6

Target Price

102.7

P/E

Forward P/E

165.87

PEG

P/S

5.34

P/B

34.99

P/Free Cash Flow

112.21

EPS

-15.18

Average EPS Est. Cur. Y

-14.92

EPS Next Y. (Est.)

0.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-102.93

Relative Volume

0.98

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-9.1

EPS 1 30Days Diff

-9.15

EBIT Estimation

◆ TARS Healthcare

$73.83

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

8/20

Pullback

13/25

Volume

7/15

Valuation

13/20

TP/AR

3/10

Options

4/10

RSI

54.1

Range 1M

80.3%

Sup Dist

7.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

16/30

Estimates

3/20

Inst/Vol

6/15

Options

5/10

EPS Yr

-878.2%

EPS NY

102.9%

52W%

54.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -53.8% upside

Quality

6/30

Valuation

1/30

Growth

12/25

Stability

5/10

LT Trend

3/5

Upside

-53.8%

Quality

TARS — P/E HistoricalBiotechnology

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 370

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS

Latest News

—

Caricamento notizie per TARS…

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: TARS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y